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Abstract: Aim. To evaluate the osteogenic potential of chalcones using the 
rat critical size calvarial defect. Methods. The chalcones were synthesized from 
acetophenone following the Claisen-Schmidt aldol condensation method by var-
ying the substituted benzaldehydes (3,4-Cl; 4-Cl; 4-CH3; 4-OCH3, H). The 
five chalcone molecules were evaluated in three concentrations (1%, 5% and 
10%) in comparison to control and vehicle (Vaseline) groups. The results of the 
remaining wound areas were calculated statistically by the ANOVA method fo-
llowed by the Student-Newman-Keuls test and the histological sections were 
analyzed qualitatively by light microscopy. Results. All molecules at 10% con-
centration showed significant bone closure compared to the control, vehicle and 
chalcone groups at 1% concentration (p<0.01). Active osteoblasts were observed 
on the repair surfaces in all groups treated with chalcones. Treatment with the 
C5 molecule at concentration of  a 10% resulted in greater bone neoformation 
compared to the other molecules, with features of secondary bone observed. 
Conclusion. The chalcones evidenced a dose-dependent osteogenic potential and 
C5 was more effective in bone repair.
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INTRODUCTION.
Bones are tough and rigid structures that, despite their inert 
appearance, grow, remold, and remain active throughout the life of 
organisms. When bone is injured, as occurs in fractures, they are capable 
of repair, a phenomenon that demonstrates their permanent vitality. 
At normal conditions, most of the fractures do not present problems 
of consolidation, however there are situations in which the repair 
process may be accelerated, ensuring a faster return of musculoskeletal 
function.1 Despite the great regenerative potential of bone tissue, in 
some cases the wound can be filled by fibrous connective tissue and the 
repair may be inadequate.2,3 
Bone reconstructions are frequent in the routine of oral and 
maxillofacial surgeries, and may be indicated in face traumas, pathologies 
and orthognathic surgeries.4 Therefore, some mechanisms used in the 
treatment of bone defects correspond to autologous, allogeneic or 
xenotransplantation transplants. However, these methods require strict 
control associated to the transmission of infectious agents.5,6 
Further, within a variety of bioactive factors, bone morphogenetic 
proteins (BMPs) have been widely studied and show satisfactory results 
regarding osteogenesis in tissue engineering areas. However, these proteins 
isolated from allogeneic or xenogenic bone have associated health risks, 
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such as the transmission of infection and the induction of 
comorbities. In addition, the clinical use of  BMPs has been 
substantially reduced due to the high cost of obtaining 
these substances.7 Limitations associated with bone repair 
and the materials that can promote the osteogenesis have 
motivated the development of alternative strategies to 
enhance the repair of large bone defects.
Through organic synthesis, many classes of organic 
compounds have shown promising biological effects.8 
Chalcones represent a group of intermediate compounds 
or end products in flavonoid biosynthesis. Considering 
that different substituents on the chalcone rings may 
result in compounds with different biological activities, 
many pharmacological studies of several synthetic 
chalcones show antioxidant, antibacterial, anti-fungal, 
antiviral, antiparasitic, analgesic, anti-inflammatory, 
cytotoxic and chemopreventive potential for cancer 
cells.9-11 Plant-isolated molecules have been shown to 
play a role in the repair of non-mineralized tissues.12-14 
However the potential of these molecules in the repair of 
bone wounds is not known.
Kim et al.,15 showed that licochalcone A has osteogenic 
activity, increasing alkaline phosphatase and calcium 
levels, interfering with cell differentiation, with a possible 
induction of the expression levels of BMPs. Moreover, 
Ortolan et al.,16 suggested induction of bone repair by 
chalcone 1-phenyl-3-(4-chlorophenyl)-2-propen-1-one in 
the rat critical size calvarial defect, as the wounds treated 
with this molecule showed complete closure after 45 days 
of treatment.
The aim of this study was to evaluate the osteogenic 
potential of five synthetic chalcone molecules with 
different substituents (3,4-Cl; 4-Cl; 4-CH3; 4-OCH3, 
H), in three concentrations (1%, 5% and 10%) on 
critical rat calvarial defects using Vaseline as a vehicle.
MATERIALS AND METHODS.
Synthesis of chalcones
The 1,3-diphenylprop-2-en-1-ones were obtained by 
the Claisen Schimdt aldol condensation method of. The 
method consisted in dissolving an equimolar mixture 
of different substituted benzaldehydes (0.05mol) and 
acetophenone (0.05mol) in 25ml of ethanol in basic 
medium (5g of sodium hydroxide).
Surgical procedure
After approval of the Ethical Committee on the Use 
of Animals of University of Vale do Itajaí (UNIVALI) 
(041/2011), 170 Wistar female rats (45 days old) were 
used. Under sterile conditions of the surgical field the 
animals were anesthetized with a solution of 3.75ml 
ketamine hydrochloride Cetamin® (10%), 2.5ml of 
Dopasen® xylazine (2%) and 3.35ml of distilled water; 
(0.1ml/kg IM) and manually trichotomized in the right 
parietal bone region.
The cutaneous and periosteal planes were folded and a 
disk of bone tissue was completely removed with a 5mm 
diameter surgical trephine mounted on a low-rotation 
handpiece, and under constant irrigation with saline, 
exposing the dura mater (Figure 1). 
The wounds of the control group (n=10) were irri-
gated with saline solution; in the vehicle group (n=10) 
Vaseline was applied (single application). In the each 
of the other groups one of the five molecules-types was 
applied (Figure 2) with vehicle at concentrations of 1%, 
5% and 10% (n=10 animals/concentration). 
Vaseline, used as a drug-carrier, was used to provide 
the drug with a semisolid form  and to carry the chalco-
ne (powder), facilitating the single administration onto 
the calvaria of the animal.
Then, the periosteum and soft tissues were sutured. 
For analgesia, ketoprofen Ketofen® 1% (0.25ml/100g) 
was applied subcutaneously within the first 72 hours.
After 30 days, the animals were euthanized with 
anesthetic overdose and the repair tissue was removed for 
analysis of the critical wound area. The collected material 
was fixed by immersion in 4% paraformaldehyde in 
phosphate buffer, pH 7.4 for 72 hours. After this period, 
for quantitative analysis the areas of the remaining 
wounds were calculated (in mm2) using Image J software 
(NIH, USA). 
Following the histological technique, the samples 
were demineralized in 10% ethylenediamine tetraacetic 
acid (EDTA) in phosphate buffer (0.1M, pH 7.4), 
dehydrated in alcohol at increasing concentrations 
(70, 90 and 100%), bleached in xylol and embedded in 
paraffin. Five semi-seriate cuts (1:10) were obtained in a 
7μm rotatory microtome and stained with hematoxylin 
and eosin.
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Macro and microscopic analysis and statistical 
treatment
The Image J software (NIH, USA) was used to measure 
the area of  critical wounds for comparison between groups. 
Quantitative data were statistically treated using variance 
analysis (ANOVA) followed by the Student-Newman-
Keuls multiple comparisons test using the GraphPad 
InStat (GraphPad, USA). The histologic sections were 
analyzed qualitatively by transmitted light microscopy, 
evaluating the cellular and tissue types in  wound repair. 
The specimens of the repair areas were documented with a 
photomicroscope (BX50, Olympus®, Tokyo, Japan).
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Figure 2.  Chemical structure of chalcones.Figure 1.  Critical wound and chalcone application.
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RESULTS.
Table 1 and Figure 3 show the mean values for the 
remaining wound areas from the critical wound, analyzed 
quantitatively in each of the groups and the doses used. 
Statistical analysis did not show significant differences 
between the control and vehicle groups regarding the 
mean area values of the remaining wounds.
The groups treated with C4 and C5 molecules at 1% 
concentration showed significant differences compared 
to the control group (p<0.01). At 5% concentration, 
the C1 and C2 chalcones showed a significant increase 
in bone wound closure compared to the control group 
(p<0.01) and the C3, C4 and C5 molecules, in this same 
concentration, show statistically significant differences in 
comparison to the control and vehicle group (p<0.01). 
At 10% concentration, all the molecules showed 
a significant increase in bone closure compared to the 
control, vehicle and chalcone at 1% concentration 
groups (p<0.01). No statistical differences were observed 
between the 5% and 10% concentrations. No significant 
differences were observed between the molecules at the 
same concentrations (Figure 3). 
Thirty days after the surgical procedure, microscopic 
analysis showed disorganized connective tissue with no 
signs of inf lammation in the control group; no significant 
bone neoformation from the edges of the critical defect 
coated by f lattened cells (inactive osteoblasts) (Figure 
4-A). Regarding the vehicle group, the wounds showed 
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Figure 3.  Areas of remaining wounds of the animals treated with chalcones (C1, C2, C3, C4 and C5) 
at 1%, 5% and 10% concentration and the control and vehicle groups after 30 days of treatment.
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inf lammatory infiltrate characterized by mononuclear 
cells and wound edges coated by inactive osteoblasts 
(Figure 4-B).
The group treated with concentrations of 1%, 5% and 
10% of chalcone displayed connective tissue and absence 
of inflammatory infiltrate at central wound areas, 
osteogenesis at the edges of the critical defect coated with 
active osteoblasts was observed (Figure 4-C, D and E). 
In the groups treated with C4 and C5 chalcones at 
10%, the repair tissue displayed a lamellar aspect with 
observed osteocytes oriented in the same direction, 
featuring secondary bone (Figure 4-F).
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DISCUSSION.
This study aimed to evaluate the osteogenic potential 
of different concentrations (1%, 5% and 10%) of chalcone 
molecules with distinct substituents as proposed by Topliss, 
using Vaseline as vehicle, in the rat critical size calvarial 
bone defect. The calvaria has been chosen as a model to 
simulate bone loss because it is an area anatomically free 
of mechanical stress, with bone defects structures stably 
surrounded, and with a limited blood supply resulting in a 
low regenerative potential.17 
In addition, a critical defect should be large enough to 
avoid spontaneous repair during the animal life, making 
the study of the osteogenic potential of a substance possible 
and to evaluate the interactions between the implanted 
material and the bone in situ.18 These considerations 
validate the experimental model used in our study.
A B
D
C
E F
OS
OP
OP
OP
TC
V
A.  Control group: inactive osteoblasts (arrows) in the bone surfaces. 
B. Vehicle group: severe inflammation in the connective tissue (CT), presence of blood vessels (V) and mononuclear cells (double arrow). 
C. C2 group-1% concentration; active osteoblasts (arrow) at the borders of the newly formed bone tissue and primary bone (OP). 
D. C4 group-5% concentration; active osteoblasts (arrows) in the bone surfaces and primary bone (OP). 
E. C3 group-10% concentration; active osteoblasts (arrows).
F. C5 group-10% concentration; bone surfaces coated by active osteoblasts (arrows), lamellar bone with concentric structures (arrowhead) featuring 
secondary bone (OS).
Figure 4.  Photomicrographs of experimental wounds.
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Groups Mean±standard error
Control 16.28±0.48
Vehicle 14.97±1.20
  Concentrations
Molecules 1% 5% 10%
C1 13.83±0.53 12.24±0.63* 9.11±1.19**
C2 14.06±0.61 11.96±0.91* 7.93±1.05**
C3 12.36±0.60* 9.53±0.62** 7.34±1.05**
C4 11.59±0.95* 9.18±0.64** 6.25±1.05**
C5 11.78±0.61* 8.58±0.53** 5.94±0.72**
Table 1.  Remaining areas of wounds 30 days after treatment.
Areas of remaining wounds of experimental groups. 
Data are presented as mean ± standard error. [*]=p<0.01; Significant for the control group; [**]=p<0.01
Significant for the control and vehicle groups. 
ANOVA followed by the Student-Newman-Keuls test, n=10 animals per group.
ISSN Online 0719-2479 - www.joralres.com © 2017214
The period of 30 days of treatment with chalcone allows 
for the measuring of the diameters of the remaining bone 
wounds, without total repair of the defect, since previous 
studies have shown that 45 days after treatment with chal-
cone a complete repair of the critical wound has occurred, 
limiting comparisons among the groups.16
The results show that both groups, control and vehicle, 
present a small area of  bone neoformation and none of the 
wounds evolved to significant regeneration during the 30 
days of the experiment, characterizing the critical wound 
model. In both groups, the osteoblasts present in the borders 
of bone wounds show a reduced ability of bone synthesis, 
suggesting limited bone formation. Oliveira et al.,19 obtained 
similar results after evaluating the critical wound repair pro-
moted by a demineralized bovine bone implant. The authors 
showed that biomaterial has been replaced by fibrous tissue 
at 21 days after treatment, and after 90 days the repair was 
still incomplete. On the other hand, the chalcone molecules 
showed osteogenic potential in our study. The vehicle-treat-
ed wounds showed inflammatory reaction with engorged 
blood vessels and mononuclear cells. Although primarily 
inflammation represents one of the defense mechanisms of 
the body, the vehicle used in this study (Vaseline) may have 
compromised the bone regeneration, because even after 30 
days this inflammatory repair phase remains evident.
Huang et al.,20 show that a suitable initial inflammatory 
response is required to initiate and guide subsequent bone 
regeneration processes. In contrast, excessive or prolonged 
inflammation may inhibit or delay the bone tissue repair. 
Thus, the anti-inflammatory property of chalcones as 
reported by Chen et al.,21 may have contributed to the 
improvement of the bone repair stimulus observed in our 
study, as in animals treated with chalcones no inflammation 
signs were observed.
Previous studies16 have shown that a single application of 
chalcone in rat calvarial defects reduces the critical defect 
size after 30 days of treatment and promotes complete 
wound closure after 45 days. In our study, we observed 
predominantly active osteoblasts on the repair surfaces 
from neoformed bone in animals treated with chalcones. 
Therefore, it is possible that chalcones induce complete 
repair of critical defects in longer periods, especially at 
10% concentration, which was the most effective dose in 
reducing critical defect size.
Although Kim et al.,15 have demonstrated that licochal-
cone A is more effective in bone repair at low concentra-
tions (2.5μM and 5μM) compared to higher doses (10μM), 
our results show that five different chalcone molecules pre-
sented osteogenesis activity in a dose-dependent manner. 
In addition, chalcones used in higher concentration (10%) 
did not present toxicity, as observed by the absence of ne-
crosis processes and already reported by Pingaew et al.22
The degree of bone repair observed with treatment with 
the different chalcone molecules at the same concentra-
tions, as measured in remaining wound area at the exper-
imental endpoint, did not differ, suggesting that all the 
assayed molecules have osteogenic potential.
Although the result was not statistically significant 
regarding the amount of bone formed, the 10% 
concentration appeared to be more effective, and treatment 
with C4 and C5 molecules resulted in higher bone 
formation compared to the other molecules, and showed 
some features of secondary bone in histological analysis.
Therefore, the repair promoted by C4 and C5 chalcones 
seems to be similar to that obtained by the autogenous 
bone graft, considered a gold standard among the materials 
used in the osteogenesis process. Trotta et al.,23 showed that 
this biomaterial was able to promote significant bone repair 
with the presence of Haversian canals in the newly formed 
bone after 30 days.
The chalcone structure formed by two aromatic rings and 
substituents proposed by Topliss, confer to these molecules 
lipophilic characteristics,24,25 enabling them to interact with 
membrane or cytoplasmic receptors of bone cells during some 
of the phases of the repair, or with  transcription factors and 
secreted non-collagenous proteins such as BMPs, responsible 
for the elaboration of extracellular matrices that mineralize. 
This data are found in a study by Kim et al.,15 regarding the 
possible induction of the expression of BMP, an important 
factor in the osteogenesis mechanism, by licochalcona A. 
In contrast, studies by Sung et al.,26 Yadav et al.,27 and 
Suh et al.,28 showed that different chalcones may also 
suppress osteoclastogenesis by inhibiting osteoclast receptors 
such as RANKL. Considering the osteogenic potential 
presented by chalcones in the present study, these molecules 
may present a pharmacological approach for the acceleration 
of bone repair. However, it is important to continue studies 
evaluating other molecules and carriers, employing other 
Ortolan XR,Mezadri TJ, Tames DR, Corrêa R &  Campos-Buzzi F. 
Osteogenic potential of different chalcones in an in vivo model: A preliminary study. 
 J Oral Res 2017;6(8):209-215. doi:10.17126/joralres.2017.059
215ISSN Online 0719-2479 - www.joralres.com © 2017
methodologies, in order to determine the factors involved 
in the process of osteogenesis promoted by these substances, 
considering the cost-benefit aspect involved in the process of 
chalcone synthesis.
CONCLUSION.
The chalcones displayed a dose-dependent osteogenic 
potential and C5 was the most effective at promoting 
bone repair.
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